Company intelligence / Profile preview

Seers Therapeutics

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Seres pioneered the first-ever FDA-approved oral live biotherapeutic (VOWST™, formerly SER-109) for recurrent C. difficile infection. Their pipeline includes programs in preclinical through Phase 3 development targeting gastrointestinal, inflammatory, metabolic, and immuno-oncology indications, with SER-109 demonstrating positive Phase 3 results and receiving approval; SER-262 and SER-287 are in early to mid-clinical stages, while SER-401 is preclinical[2].

Therapeutic areas: ImmunologyGastroenterologyInfectious DiseasesMetabolic DisordersOncology
Modalities: Live biotherapeutic product therapyMicrobial therapyBiologic
Industry: Biotech

Partnerships

Nestlé Health ScienceThe University of Texas MD Anderson Cancer CenterParker Institute for Cancer Immunotherapy

Beyond the preview

Go deeper on Seers Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Seers Therapeutics.

Explore the full profile